Abstract Number: 2181 • ACR Convergence 2023
Secretagogue Effect of PDE4 Inhibitor Apremilast on Human Salivary Gland Organoids Obtained from Primary Sjögren’s Syndrome Patients
Background/Purpose: In primary Sjögren's syndrome (pSS), salivary epithelial cells show an active role in the initiation and reiteration of the immunomediated damage. Epithelial saliva production…Abstract Number: 2223 • ACR Convergence 2023
Relationship Between Sleep Quality, Disease Activity, and Psychological Factors in Patients with Axial Spondyloarthritis: A Cross Sectional Study
Background/Purpose: Sleep problems are prevalent in 30-70% of patients with axial Spondyloarthritis (SpA), negatively impacting their quality of life. Poor sleep quality in these patients…Abstract Number: 2224 • ACR Convergence 2023
Difficult to Treat Axial Spondyloarthritis. Predictors of Poor Outcomes
Background/Purpose: The term "Difficult-to-Treat" (D2T) defines those patients who remain active despite having undergone various treatments within the established recommendations. This concept is defined by…Abstract Number: 2182 • ACR Convergence 2023
Mitochondrial Alterations in Primary Sjögren´s Syndrome
Background/Purpose: Primary Sjögren's Syndrome (pSS) is a systemic autoimmune disorder characterized by lymphocytic infiltrations in exocrine glands. T-cells are considered major players in the pathogenesis…Abstract Number: 2177 • ACR Convergence 2023
Characterization of Crevicular Fluid Microbiota in Primary Sjögren’s Syndrome
Background/Purpose: To describe the taxonomic composition of the microbiota in the crevicular fluid of patients with primary Sjögren's syndrome (PSS), and to assess their association…Abstract Number: 2229 • ACR Convergence 2023
Individual Entheseal Points Have Differential Frequency of Involvement and Impact on Patient Reported Outcomes in Patients with Active Psoriatic Arthritis: Pooled Analysis of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies
Background/Purpose: In patients with mono/oligoarticular psoriatic arthritis (PsA), swelling or tenderness of specific joints can be associated with poorer patient-reported outcomes (PROs) and physician global…Abstract Number: 2228 • ACR Convergence 2023
Early Improvement in 3 Visual Analogue Scale (3VAS)/4VAS Predicts Reduced Rates of Radiographic Change in Bio-naive Active Psoriatic Arthritis Patients Receiving Guselkumab Treatment
Background/Purpose: Guselkumab (GUS), a fully human IL-23p19 subunit inhibitor, was shown to reduce mean changes in radiographic progression vs placebo (PBO) by week (W)24 and…Abstract Number: 2221 • ACR Convergence 2023
Clinical and Molecular Patterns Associated with Persistence of Inflammation in Spondyloarthritis Patients: Unveiling Potential Biomarkers
Background/Purpose: Chronic inflammation is closely associated with an increased risk of cardiovascular diseases (CVD) through the activation of the immune system and the release of…Abstract Number: 2185 • ACR Convergence 2023
35 Years Follow-up of Primary Sjögren’s Disease: A Single Center Study
Background/Purpose: Primary Sjögren’s syndrome (pSS) is an autoimmune rheumatic disease characterized by lymphocytic infiltration of exocrine glands. Its clinical manifestations are heterogeneous. Currently, the evidence…Abstract Number: 2193 • ACR Convergence 2023
Anti-citrullinated Protein Antibodies in Sjögren’s Syndrome Define a Subset of Patients with Lower B Cell Activation Markers and Higher Risk of Lung Involvement
Background/Purpose: Extraglandular manifestations may occur in up to 40-50% of patients with SS, including inflammatory arthralgia and chronic polyarthritis (1-3). ACPA are prototypical markers of…Abstract Number: 2188 • ACR Convergence 2023
Lung Cysts in Primary SS: New Findings on an Allegedly Innocuous Iiagnosis
Background/Purpose: Lung cysts are a frequent finding in patients with SS, with previous data indicating a prevalence of approximately 30% on chest CT scans. In…Abstract Number: 2192 • ACR Convergence 2023
New Inducible Mouse Model of Sjögren’s Syndrome Represents a Valuable Tool to Assess the Impact of Gene Knockout on the Disease’s Physiopathology
Background/Purpose: Primary Sjögren's syndrome (pSS) is a chronic rheumatic disease characterized by lymphocytic infiltration of exocrine glands, resulting in sicca syndrome with extra-glandular autoimmune features.…Abstract Number: 2208 • ACR Convergence 2023
Awareness and Attitudes Regarding Axial Spondyloarthritis Among Non-Rheumatology Physicians in the United States
Background/Purpose: Average diagnostic delay for axial spondyloarthritis (axSpA) is 7 to 10 years. Lack of timely referral of inflammatory back pain (IBP) patients by non-rheumatology…Abstract Number: 2215 • ACR Convergence 2023
Can Axial Spondyloarthritis Unequivocally Be Diagnosed by Rheumatologists in Patients with Chronic Back Pain of Less Than Two Years Duration? The Primary Outcome of the Two-year SPondyloArthritis Caught Early (SPACE) Cohort
Background/Purpose: Unacceptable diagnostic delay in axial Spondyloarthritis (axSpA) remains an issue. In 2008, the longitudinal SPondyloArthritis Caught Early (SPACE)-cohort started to assess the prevalence of…Abstract Number: 2236 • ACR Convergence 2023
Guselkumab Provides Rapid Clinically Meaningful Improvements in Clinical and Patient Reported Outcomes and Sustained Disease Control of Psoriatic Arthritis
Background/Purpose: Guselkumab (GUS) has demonstrated robust efficacy across key PsA domains at Week (W) 24, with effects sustained or further enhanced through 2 years. Timing…
- « Previous Page
- 1
- …
- 342
- 343
- 344
- 345
- 346
- …
- 2425
- Next Page »